Prognostic value of vascular endothelial growth factor in patients with head and neck cancer: A meta-analysis.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 22987573.
- Also identified by DOI 10.1002/hed.23156.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The correlation between vascular endothelial growth factor (VEGF) overexpression and the clinical outcome of head and neck cancer remains inconclusive. This meta-analysis aimed to evaluate the prognostic value of VEGF in patients with head and neck cancer. We searched Ovid MEDLINE, EMBASE and 2 Chinese science databases in order to enroll all eligible articles. Forty-seven studies were included in this meta-analysis. All results were evaluated by the random-effects model. VEGF overexpression is significantly associated with worse overall survival (OS; hazard ratio [HR], 1.89; 95% confidence interval [CI], 1.61-2.22) and progression-free survival (PFS; HR, 1.68; 95% CI, 1.33-2.12). Subgroup analysis reveals that VEGF overexpression is a significant poor predictor for nasopharyngeal cancer (HR, 1.66; 95% CI, 1.30-2.12) and salivary gland cancer (HR, 3.32; 95% CI, 1.61-6.84). Our meta-analysis supports that VEGF overexpression is an available poor predictor for patients with head and neck cancer.
Medical subject headings
- Carcinoma, Squamous Cell
- Head and Neck Neoplasms
- Vascular Endothelial Growth Factor A